Onco Actu du 14 décembre 2017

	2.7 Etiologie - Obésité
Diabetes and obesity both tied to higher risk of cancer [Reuters] The biggest proportion of cancer cases related to diabetes and high BMI - about 38 percent - occurred in high-income western countries, followed by east and southeast Asian countries at about 24 percent.
	3.1 Prévention - Tabac
Marijuana and Vaping Are More Popular Than Cigarettes Among Teenagers [NY Times] The report, sponsored by the federal government’s National Institute on Drug Abuse and administered by the University of Michigan, found that 22.9 percent of high school seniors said they had used marijuana within the previous 30 days and 16.6 percent had used a vaping device. Only 9.7 percent had smoked cigarettes.
	4. Dépistage, diagnostic et pronostic
The Less-Is-More Crusade — Are We Overmedicalizing or Oversimplifying? [NEJM] Possibility is not the same as probability, but when you’re bearing the weight of another person’s life, the distinction often feels meaningless.
	4.12 Biopsies liquides
New, simple blood tests for prostate cancer [Institute of Cancer Research] “We are now beginning a new clinical trial, involving up to 600 men, in which we aim to show that patients who test positive for these genetic mutations get significantly greater benefit from chemotherapy compared to abiraterone. If the clinical trial has positive results, we could see the liquid biopsy adopted into more routine clinical practice in prostate cancer.”
	5. Traitements
Building the clinical evidence on metformin and cancer [Cancer World] Population studies, mouse models, and mechanistic studies all show that metformin, a cheap well-tolerated diabetes drug, impacts in some way on how some cancers develop and progress. Anna Wagstaff talks to clinicians and researchers building the evidence on what it can deliver in the clinic.
	5.12.1 Immunothérapies - partenariats
Bristol-Myers boosts I-O offering with new Ono drug deal [FierceBiotech] Bristol has been ramping up the deals in recent years, with much spent on Padlock and Flexus, and just a few months back, BMS struck a potential multi-billion biobucks deal with for IFM Therapeutics and its new immuno-oncology approaches.
Bristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Factors in the Tumor Microenvironment [BMS] Bristol-Myers Squibb to develop and commercialize ONO-4578, Ono’s Phase 1 selective Prostaglandin E 2 (PGE 2 ) receptor 4 (EP 4 ) antagonist.
	5.12.3 Immunothérapies-combinaisons
New clues to boosting checkpoint inhibition in lung cancer [FierceBiotech] The researchers believe that targeting mutated Ras along with PD-L1 may make checkpoint inhibitors more effective.
	5.12.5 Immunothérapies - Pharma
U.S. Food and Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma and Grants Priority Review [BMS] Application based on results from phase 3 CheckMate -214 study.
Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd? [EndPoints] Top investigators in the program have highlighted their belief that PD-1 is a fundamentally superior approach than PD-L1 — though they have yet to prove that.
	5.12.8 Immunothérapies - Economie
Pionyr Immunotherapeutics gains meaty $62M series B [FierceBiotech] Krummel has been a pioneer in immuno-oncology since the mid-1990s and was one of the inventors behind Bristol-Myers Squibb’s first checkpoint inhibitor Yervoy (ipilimumab).
Yervoy inventor’s oncology startup Pionyr gets $62M for tumor-fighting tech [EndPoints] Pionyr’s tech, which the company calls “Myeloid Tuning,” attempts to rebalance the tumor microenvironment to favor immune-activating myeloid cells.
	5.2 Pharma
Eli Lilly builds $23B-plus sales forecast on diabetes, cancer launches [FiercePharma] In its annual presentation of its outlook for the year ahead, Lilly said on Wednesday that its 2018 growth will be driven by its newest diabetes drugs—Trulicity, Basaglar and Jardiance—plus plaque psoriasis treatment Taltz and cancer offerings Verzenio, Cyramza, and Lartruvo.
Sanofi faces a make-or-break year, saying it’s ready to put a 3-prong R&D strategy to a pivotal test [EndPoints] They heralded the positive pivotal data for their PD-1 cancer checkpoint drug cemiplimab, also partnered with Regeneron. The pipeline review notes that Sanofi is taking this treatment into a pivotal program for frontline lung cancer — a field that has attracted the intense interest of every major checkpoint player.
	5.2.1 Pharma - Partenariats
Daiichi Sankyo: Two steps forward, one step back in cancer deals [Pharmafile] Daiichi Sankyo had a busy day in terms of its deals in oncology, not only did it tear up its agreement with Nektar Therapeutics but it also signed up for two more deals yesterday.
Daiichi ditches Nektar following cancer drug flop [EndPoints] The duo was gambling on an early approval for Onzeald after researchers extracted data from their BEACON study on 67 advanced breast cancer patients with a history of brain metastases. The Committee for Medicinal Products for Human Use was not impressed.
	5.3.4 Traitements - AMM (FDA, EMA)
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer [Bayer] Approval based on data from the Phase III RESORCE study where Stivarga® (regorafenib) demonstrated significant improvement in overall survival in hepatocellular carcinoma (HCC) patients previously treated with Nexavar® (sorafenib).
	5.7 SABCS
First-line Ribociclib Improves PFS in Pre- and Peri-menopausal Women with HR-positive, HER2-negative Advanced Breast Cancer [ESMO] MONALEESA-7, the first dedicated trial investigating addition of CDK4/6 inhibitor ribociclib to standard endocrine therapy with temporary ovarian suppression.
	5.8.4 ASH - CAR T
Preliminary Data from Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials [Cellectis] The CALM study (UCART19 in Advanced Lymphoid Malignancies) is an open label, dose-escalation study designed to evaluate the safety, tolerability and anti-leukemic activity of UCART19 in adult patients with R/R B-ALL.
	6. Lutte contre les cancers
French researchers hope new chief will revitalize troubled funding agency [Nature] Microbiologist Thierry Damerval appointed head of France’s National Research Agency.
	6.1 Observation
Head and neck cancer survivors have long-lasting cognitive problem [Reuters] The findings are drawn from cognitive assessments for 80 survivors of these tumors and a control group of 40 otherwise similar people who didn’t have these malignancies. Two years after cancer treatment, 38 percent of the survivors had impaired cognitive functioning, but nobody in the control group did.
	6.11 Patients
Joe Biden Comforts Meghan McCain in Heartfelt Exchange on ‘The View’ [NY Times] On the show, Mr. Biden moved to comfort Ms. McCain by sharing information about new treatment for glioblastoma. “If anybody can make it,” he told Ms. McCain, it’s your father.
	6.6 Publications
The science that’s never been cited [Nature] Of all biomedical-sciences papers published in 2006, just 4% are uncited today; in chemistry, that number is 8% and in physics, it is closer to 11%.
	6.7.2 Applis
Janssen Oncology rolls out Cancer.com, a website that's been years in the making [FiercePharma] The overall idea? Create a site that's full of info and resources but doesn't swamp patients already exposed to an onslaught of news and information about cancer everywhere they look.
Janssen and Leading Advocacy Organizations Introduce Cancer.com, a Customizable Online Destination for People Impacted by Cancer [Johnson&Johnson] Cancer.com features content tailored to each user plus a wealth of resources, including My Care Activator™, an exclusive digital health coaching tool.